Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

NCT02634827 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia With FLT3/ITD Mutation
Acute Myeloid Leukemia With Gene Mutations
FLT3 Tyrosine Kinase Domain Point Mutation
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: Decitabine
OTHER: Laboratory Biomarker Analysis
DRUG: Midostaurin

Sponsor

Mayo Clinic

Collaborators

[object Object]